Alimentary Pharmacology & Therapeutics

Herbal medicinal products for non-ulcer dyspepsia
pp. 1689-1699(11)
Authors: Thompson Coon, J.; Ernst, E.

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome
pp. 1701-1708(8)
Authors: Tougas, G.; Snape, W. J.; Otten, M. H.; Earnest, D. L.; Langaker, K. -E.; Pruitt, R. E.; Pecher, E.; Nault, B.; Rojavin, M. A.

Alimentary diseases in the poor and middle class in London 1773-1815, and in New York poor 1797-1818
pp. 1709-1714(6)
Authors: Baron, J. H.; Sonnenberg, A.

The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma
pp. 1715-1722(8)
Authors: Caletti, G.; Zinzani, P. L.; Fusaroli, P.; Buscarini, E.; Parente, F.; Federici, T.; Peyre, S.; De Angelis, C.; Bonanno, G.; Togliani, T.; Pileri, S.; Tura, S.

The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis
pp. 1723-1731(9)
Authors: Annibale, B.; Di Giulio, E.; Caruana, P.; Lahner, E.; Capurso, G.; Bordi, C.; Delle Fave, G.

Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of Helicobacter pylori infection
pp. 1733-1738(6)
Authors: Bilardi, C.; Biagini, R.; Dulbecco, P.; Iiritano, E.; Gambaro, C.; Mele, M. R.; Borro, P.; Tessieri, L.; Zentilin, P.; Mansi, C.; Vigneri, S.; Savarino, V.

Efficacy of enzyme immunoassay for the detection of Helicobacter pylori antigens in frozen stool specimens: local validation
pp. 1739-1742(4)
Authors: Yee, Y. K.; Yip, K. T.; Que, T. L.; Chang, K. K.; Li, K. F.; Lee, C. K.; Wong, S. W.; Lau, S. F.; Szeto, M.L.

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease
pp. 1743-1750(8)
Authors: Ansari, A.; Hassan, C.; Duley, J.; Marinaki, A.; Shobowale-Bakre, E. -M.; Seed, P.; Meenan, J.; Yim, A.; Sanderson, J.

Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission
pp. 1751-1759(9)
Authors: Paoluzi, O. A.; Pica, R.; Marcheggiano, A.; Crispino, P.; Iacopini, F.; Iannoni, C.; Rivera, M.; Paoluzi, P.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease
pp. 1761-1770(10)
Authors: Yacyshyn, B. R.; Barish, C.; Goff, J.; Dalke, D.; Gaspari, M.; Yu, R.; Tami, J.; Dorr, F. A.; Sewell, K. L.

Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules
pp. 1771-1779(9)
Authors: Tuleu, C.; Basit, A. W.; Waddington, W. A.; Ell, P. J.; Newton, J. M.

Performance characteristics of scintigraphic transit measurements for studies of experimental therapies
pp. 1781-1790(10)
Authors: Cremonini, F.; Mullan, B. P.; Camilleri, M.; Burton, D. D.; Rank, M. R.

Gabexate mesilate and/or octreotide in human immunodeficiency virus-associated pancreatic abnormalities
pp. 1791-1794(4)
Authors: Manfredi, R.; Calza, L.; Chiodo, F.

Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease
pp. 1795-1800(6)
Authors: Spechler, S. J.; Jain, S. K.; Tendler, D. A.; Parker, R. A.

Prokinetic effect of indoramin, an α-adrenergic antagonist, on human gall-bladder
pp. 1801-1803(3)
Authors: Sengupta, S.; Cooney, R.; Baj, M.; Ni'Muircheartaigh, R.; O'Donnell, L. J. D.

Serum pepsinogen can predict response to H2-receptor antagonist in patients with functional dyspepsia
pp. 1805-1809(5)
Authors: Yoshikawa, I.; Murata, I.; Kume, K.; Kanagawa, K.; Hirohata, Y.; Nakamura, H.; Otsuki, M.

Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers
pp. 1811-1817(7)
Authors: Saitoh, T.; Fukushima, Y.; Otsuka, H.; Hirakawa, J.; Mori, H.; Asano, T.; Ishikawa, T.; Katsube, T.; Ogawa, K.; Ohkawa, S.

Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease
pp. 1819-1829(11)
Authors: Gardner, J. D.; Rodriguez-Stanley, S.; Robinson, M.; Miner, P. B.

Drug side-effects in IBD
pp. 1831-1831(1)
Authors: Massironi, S.; Losco, A.; Basilisco, G.

Infliximab and Crohn's QOL
pp. 1831-1832(2)
Authors: Wicks, A. C. B.; Thomas, C.; Curran, R.; Mayberry, J. F.